However, this preliminary study has allowed re-designing a 12-color panel combining backbone markers from the EF AML/MDS panel with the myeloid lineage-associated markers, such as CD13, CD64, CD36, CD105, CD71, and CD33 that could improve the discriminatory potential between myHPCs and AML blasts. This evidence concerns the gene ANPEP and myelodysplastic syndrome.